Skip to main content
LZAGY logo

Lonza Group AG (LZAGY) Stock Price & Analysis

Lonza Group AG (LZAGY) — price $79.11 (+0.23%), as of the Nov 19, 2026 trading session; market cap $56.3B.

Educational signal · not a buy or sell recommendation · How to read this

$79.11 +$0.18 (+0.23%) Market Cap $56.3B

Lonza Group AG · LZAGY · Healthcare · Biotechnology

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RPRX · Royalty Pharma plc · 73 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • GMAB · Genmab A/S · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$79.11
Change on the day+0.23%
52-week range$58.53–$82.63
Market capitalisation$56.3B—
Price / earnings (trailing)41.62
Shares traded on the day38.1K
Beta (volatility vs the S&P 500)0.84

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $59, high $81, latest $79. $81 $59 high $81 Oct 17, 2025 Nov 19, 2026 · $79 $70Oct 17, 2025$69Oct 31, 2025$69Nov 14, 2025$69Nov 28, 2025$65Dec 12, 2025$68Dec 26, 2025$69Jan 9, 2026$71Jan 23, 2026$67Feb 6, 2026$69Feb 20, 2026$66Mar 6, 2026$59Mar 20, 2026$64Apr 2, 2026$69Apr 17, 2026$61May 1, 2026$60May 15, 2026$64May 29, 2026$62Jun 12, 2026$66Jun 26, 2026$73Jul 10, 2026$67Jul 24, 2026$71Aug 7, 2026$74Aug 21, 2026$70Sep 4, 2026$66Sep 18, 2026$68Oct 2, 2026$73Oct 16, 2026$78Oct 30, 2026$79Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Lonza Group AG (LZAGY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Negative
Gross Margin Neutral

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Lonza Group AG (LZAGY), and what does it report?

Short answer · as of

Lonza principally sells development, scale-up and manufacturing capability rather than relying on an internal drug pipeline.

Research dated 2026-09-12.

Its customers buy support across biologics, small molecules, cell and gene therapies, personalized medicine, capsules, dosage forms and health ingredients.

Revenue therefore reflects customer programs moving through development and manufacturing, along with commercial demand flowing through installed capacity. The quoted security trades over the counter, while the operating statements describe the broader Lonza Group and its mix of service and product businesses.

2 · Latest results

What do the latest results show for Lonza Group AG (LZAGY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 3.45B. Against analyst estimates the company has EPS beat 1 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 3.45BCHF 604MCHF 0.86 (diluted)
Q4 FY2025CHF 2.96BCHF 523MCHF 0.75 (diluted)
Q2 FY2025CHF 3.58BCHF 426MCHF 0.61 (diluted)
Q4 FY2024CHF 3.52BCHF 307MCHF 0.43 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Lonza Group AG (LZAGY)?

Short answer · as of

The distress and quality screens read Altman Z 4.30 · Piotroski F 8. Trailing ratios: ROE 13.9% · ROA 6.1% · current ratio 1.66 · earnings yield 2.4% · free-cash-flow yield 0.3%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
  • Rich valuation — a P/E of 41.62 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LZAGY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LZAGY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Lonza Group AG (LZAGY)?

Read these with our analysis →

What Investors Ask About Lonza Group AG (LZAGY) — Healthcare

The last question is answered from this page's own dated data, not from the research.

What does Lonza's Biologics segment sell?

Biologics provides contract development and manufacturing across clinical and commercial stages. Demand follows customer therapies as they advance, scale and require ongoing production.

Why does Lonza's extended site shutdown matter for sales?

The shutdown allows capital work to progress but removes manufacturing availability during part of the period. Management expects that interruption to offset earlier performance and leave the affected operation broadly flat.

What is the LZAGY stock price today?

The last price recorded for Lonza Group AG (LZAGY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 13 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • 1. What is Lonza Group AG (LZAGY), and what does it report?: Legal name; Ticker / exchange; Sector / industry (provider taxonomy); Business description
  • FAQ: What does Lonza's Biologics segment sell?: Business description
  • FAQ: Why does Lonza's extended site shutdown matter for sales?: Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.